drugset / Trial / NCT01650506
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Phase 1
Completed
8 enrolled
Columbia University
Astellas Pharma Inc · collabSusan G. Komen Breast Cancer Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
Extended phase 1 trial of combined metformin and erlotinib in advanced triple negative breast cancer patients. The goals of the study are to establish the maximum tolerated combined dosing of erlotinib and metformin as well as deciding if there is a potential clinical utility of the combination in treating patients with triple negative breast cancer.
Timeline
- Start
- 2012-07
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | — |
| Subject | Metformin | Small molecule | 850 mg | — |